Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Current epidemiology of multidrug‐resistant gram‐negative bacilli in the United States.

Kallen AJ, Srinivasan A.

Infect Control Hosp Epidemiol. 2010 Nov;31 Suppl 1:S51-4. doi: 10.1086/655996.

PMID:
20929371
2.

Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.

McGowan JE Jr.

Am J Med. 2006 Jun;119(6 Suppl 1):S29-36; discussion S62-70. Review.

PMID:
16735148
3.

Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit.

Maragakis LL.

Crit Care Med. 2010 Aug;38(8 Suppl):S345-51. doi: 10.1097/CCM.0b013e3181e6cbc5. Review.

PMID:
20647792
4.

Multi-resistant Gram-negative bacilli: from epidemics to endemics.

Cantón R, Coque TM, Baquero F.

Curr Opin Infect Dis. 2003 Aug;16(4):315-25. Review.

PMID:
12861084
5.

[Antimicrobial therapy in severe infections with multidrug-resistant Gram-negative bacterias].

Duszyńska W.

Anestezjol Intens Ter. 2010 Jul-Sep;42(3):160-6. Review. Polish.

PMID:
21413423
6.
7.

The current state of multidrug-resistant gram-negative bacilli in North America.

Nicasio AM, Kuti JL, Nicolau DP.

Pharmacotherapy. 2008 Feb;28(2):235-49. doi: 10.1592/phco.28.2.235. Review.

PMID:
18225969
8.
9.

Resistant gram-negative infections.

Fraimow H, Nahra R.

Crit Care Clin. 2013 Oct;29(4):895-921. doi: 10.1016/j.ccc.2013.06.010. Epub 2013 Aug 13. Review.

PMID:
24094384
10.

The antibiotic development pipeline for multidrug‐resistant gram‐negative bacilli: current and future landscapes.

Talbot GH.

Infect Control Hosp Epidemiol. 2010 Nov;31 Suppl 1:S55-8. doi: 10.1086/655988. Review.

PMID:
20929372
11.

Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact.

Trecarichi EM, Tumbarello M.

Curr Opin Infect Dis. 2014 Apr;27(2):200-10. doi: 10.1097/QCO.0000000000000038. Review.

PMID:
24573013
12.

[Antibacterial drug resistance in Latin America: consequences for infectious disease control].

Casellas JM.

Rev Panam Salud Publica. 2011 Dec;30(6):519-28. Review. Spanish.

13.

[Epidemiology of multi-drug resistant gramnegative bacilli].

Ruiz-Garbajosa P, Cantón R.

Rev Esp Quimioter. 2016 Sep;29 Suppl 1:21-5. Review. Spanish.

14.

Evolution of β-lactams resistance in Gram-negative bacteria in Tunisia.

Chouchani C, Marrakchi R, El Salabi A.

Crit Rev Microbiol. 2011 Aug;37(3):167-77. doi: 10.3109/1040841X.2011.552880. Epub 2011 Mar 26. Review.

PMID:
21438848
15.

Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients.

Cohen J.

J Antimicrob Chemother. 2013 Mar;68(3):490-1. doi: 10.1093/jac/dks460. Epub 2012 Nov 14. Review.

PMID:
23152481
16.

Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe.

Souli M, Galani I, Giamarellou H.

Euro Surveill. 2008 Nov 20;13(47). pii: 19045. Review.

17.

Antimicrobial resistance among gram-negative organisms in the intensive care unit.

Clark NM, Patterson J, Lynch JP 3rd.

Curr Opin Crit Care. 2003 Oct;9(5):413-23. Review.

PMID:
14508155
18.

Multidrug-Resistant Gram-Negative Bacilli: Infection Control Implications.

Adler A, Friedman ND, Marchaim D.

Infect Dis Clin North Am. 2016 Dec;30(4):967-997. doi: 10.1016/j.idc.2016.08.001. Epub 2016 Sep 19. Review.

PMID:
27660090
19.

The role of gram-negative bacteria in healthcare-associated pneumonia.

Restrepo MI, Anzueto A.

Semin Respir Crit Care Med. 2009 Feb;30(1):61-6. doi: 10.1055/s-0028-1119810. Epub 2009 Feb 6. Review.

PMID:
19199188
20.

Antimicrobial resistance in Europe and its potential impact on empirical therapy.

Rossolini GM, Mantengoli E.

Clin Microbiol Infect. 2008 Dec;14 Suppl 6:2-8. doi: 10.1111/j.1469-0691.2008.02126.x. Review.

Supplemental Content

Support Center